Pain Management Drugs Market Companies, Corporate Milestones and Mergers and Acquisitions (M&A)

Top Companies in the Pain Management Drugs Market

The global pain management drugs market is rapidly growing, driven by FDA approvals, innovative non-opioid therapies, and increasing investments in R&D. Leading pharmaceutical companies are advancing personalized, safer, and more effective pain treatments for patients worldwide.

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca
• Bayer AG
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Endo International plc
• GlaxoSmithKline (GSK)
• Grünenthal GmbH
• Johnson & Johnson (Janssen Pharmaceuticals)
• Mallinckrodt Pharmaceuticals
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

Pain Management Drugs Market Forecast

The global pain management drugs market size is calculated at USD 84.1 billion in 2024, grew to USD 87.58 billion in 2025, and is projected to reach around USD 126.17 billion by 2034. The market is expanding at a CAGR of 4.14% between 2025 and 2034.

Pain Management Drugs Market Trends

FDA Approval: Regulatory agencies like the U.S. Food and Drug Administration (FDA) regulate the approval of pain management drugs.

• In January 2025, Vertex Pharmaceuticals, Inc. announced that the FDA approved JOURNAVX (suzetrigine) for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor. It is the first new class approved in more than 20 years.

Increasing Investments: Pharmaceutical startups raise funding to develop novel pain management drugs and expand their product pipeline.

• In December 2024, SiteOne Therapeutics announced that it raised $100 million in funding to conduct clinical trials for its non-opioid drug. The company develops a drug that targets the ion channel, NaV1.8, which has demonstrated its ability to reduce multiple kinds of pain.

Value Chain Analysis - Pain Management Drugs Market

R&D

R&D activities for pain management drugs result in the development of personalized therapy and non-addictive prescription medicines. Researchers also develop new delivery systems to provide targeted treatment.

Key Players: Vertex Pharmaceuticals, Inc., Johnson & Johnson, and Novartis AG.

Clinical Trials & Regulatory Approvals

Clinical trials are conducted to assess the safety and efficacy of new drug candidates or to assess the therapeutic potential of licensed medicines for extended applications. Based on the clinical trials data, regulatory agencies provide marketing approval to the drug.

Key Players: Propella Therapeutics, Johnson & Johnson, Medidata

Patient Support & Services

Patient support & services refers to providing tailored medications to patients and monitoring for their side effects. Healthcare professionals also explain the dose and delivery system to patients.

Latest Announcement by Industry Leaders

Reshma Kewalramani, M.D., CEO and President of Vertex, commented that the approval of JOURNAVX is a historic milestone for 80 million Americans who are prescribed a medicine for moderate-to-severe acute pain annually. The company has the opportunity to change the paradigm of acute pain management and establish a new standard of care.

Recent Developments in the Pain Management Drugs Market

• In May 2025, researchers from the National Institute of Health (NIH) reported positive results from its first-in-human clinical trials evaluating resiniferatoxin (RTX) for its safety and effectiveness. RTX is a non-addictive drug that is derived from a cactus-like plant used for pain control in patients with intractable cancer pain.
• In May 2024, Medidata announced that it had been selected by Lexicon Pharmaceuticals, Inc. to help advance PROGRESS, a Phase 2b study of LX9211 in diabetic peripheral neuropathic pain. The drug has the potential to become the first new, non-opioid drug approved for neuropathic pain in over two decades.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com